Methods: We conducted a two visit random-order double-blinded placebo-controlled cross-over trial in 10 healthy females living with overweight (age 27 (23-42) years weight 75 (61-80) kg). Here, we examined whether sumatriptan, a 5HT 1B-receptor agonist used to treat migraine, can affect blood glucose homeostasis in humans. Evidence from mouse models suggests that brain serotonergic pathways control blood glucose. Wellcome Trust MRC Institute of Metabolic Science, University of Cambridge, Cambridge, UKīackground: There is growing interest in the potential for new diabetes therapies to act centrally via brain glucoregulatory pathways. P2 Sumatriptan exerts glucoregulatory effects in humans PYY (3-36) could be developed as treatment for obesity with type 2 diabetes without negative implications for bone health. P1NP and CTX reduce significantly as a response to nutrient intake. P1NP and CTX reduced significantly during the MMT compared to the fasting state both prior and 4 weeks after the infusion of PYY (3-36).Ĭonclusions: Infusion of PYY (3-36) for 4 weeks does not affect the bone turnover markers in obese patients with type 2 diabetes. Results: There was no significant difference in bone markers before and after the intervention. Urinary NTX was measured at fasting state only. Bone markers (plasma P1NP, CTX, OC) were measured at the beginning and the end of the 4 weeks both at fasting state and during the MMT. Metabolic profiling at fasting state and during a Mixed Meal Test (MMT) was performed prior to the initiation of the infusion and at the end of 4 weeks. An infusion of PYY (3-36) was administered daily for up to 16 hours for a duration of 4 weeks. Methods: Ten obese patients with type 2 diabetes on diet or one hypoglycaemic agent were enrolled in the study.
Animal data have suggested that PYY may act on the bone remodelling process by increasing bone resorption.Īims: The aim of our study was to assess the effect of PYY infusion on bone turn over markers in obese patients with type 2 diabetes.
PYY has mainly been studied for its effect on appetite suppression and lately for its role in diabetes remission post-bariatric surgery. Tan 1ġ Metabolism, Digestion and Reproduction, Imperial College London, London, UK 2 Clinical Biochemistry, North West London Pathology, Imperial College Healthcare NHS Trust, London, UKīackground: Gut hormones have emerged as new promising therapies for the treatment of obesity and type 2 diabetes as well as viable alternatives to bariatric surgery. Basic and clinical science posters: Actions, metabolism and therapy P1 The effect of PYY (3-36) on bone turnover markers in obese patient with type 2 diabetes
0 kommentar(er)
